Gary Palmer
About Gary Palmer
Gary Palmer is the Chief Medical Officer of Oncology at BillionToOne, where he launched Northstar Select™ and Northstar Response™ liquid biopsy assays for commercial use.
Gary Palmer Chief Medical Officer
Gary Palmer holds the position of Chief Medical Officer in the Oncology department at BillionToOne. He is responsible for overseeing the clinical and medical aspects of the company's oncology initiatives. His role involves ensuring that medical strategies align with the company's goals and adhering to high standards in patient care and treatment development.
BillionToOne Chief Medical Officer
As the Chief Medical Officer at BillionToOne, Gary Palmer plays a crucial role in the company’s oncology division. BillionToOne focuses on developing innovative molecular diagnostics tools, and Gary's contribution is pivotal in advancing the medical facets of these initiatives. He ensures that the clinical guidelines and procedures are rigorously followed to support the company's mission.
Gary Palmer and Northstar Select™
Gary Palmer has been instrumental in launching the Northstar Select™ Liquid Biopsy Assay for commercial use. This diagnostic tool is designed to aid in the detection and monitoring of cancer by analyzing biomarkers in blood samples. It represents a significant advancement in non-invasive cancer diagnostics, providing new options for patient screening and monitoring.
Northstar Response™ Launch by Gary Palmer
Under Gary Palmer’s leadership, BillionToOne introduced the Northstar Response™ Liquid Biopsy Assay to the market. This product aims to offer detailed insights into cancer progression and response to treatment through liquid biopsy technology. The launch of Northstar Response™ demonstrates Gary’s commitment to enhancing the precision and effectiveness of cancer diagnostics.